Table 4.
Cox regression hazard ratios for survival from start of 2L therapy
| Comparator | Reference | HR (95% CI) | p value |
|---|---|---|---|
| Treatment | |||
| 2L non-taxane therapy | 2L taxane therapy | 2.46 (1.29–4.66) | <0.01 |
| Age | |||
| ≥ 65 years | < 65 years | 0.56 (0.30–1.05) | 0.07 |
| Sex | |||
| Female | Male | 0.41 (0.20–0.83) | 0.01 |
| Race | |||
| Black or African American | White | 0.79 (0.35–1.77) | 0.56 |
| Asian | 0.57 (0.14–2.34) | 0.43 | |
| Other | 0.63 (0.24–1.66) | 0.35 | |
| Missing | 1.38 (0.39–4.95) | 0.62 | |
| US geographic region | |||
| South | Midwest | 1.92 (0.68–5.42) | 0.22 |
| Northeast | 0.94 (0.31–2.81) | 0.91 | |
| West | 1.85 (0.50–6.86) | 0.36 | |
| Unknown | 1.45 (0.32–6.48) | 0.63 | |
| Disease stage at initial diagnosis | |||
| Stage IV | Stage I–III | 1.46 (0.72–2.94) | 0.30 |
| ECOG status at 2L start | |||
| ECOG PS 2–4 | ECOG PS 0–1 | 2.85 (1.16–6.97) | 0.02 |
| Missing | 1.01 (0.53–1.92) | 0.99 | |
CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance score, HR hazard ratio